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Abstract: The bronchodilator effect of fenoterol hydrobromide (0.5, 1.25, and 2.5 mg)
was compared with either isoproternol (2.8 mg) or isoetharine (5 mg) with phenyl-
ephrine (1.25 mg) in a double-blind placebo-controlled study. When delivered by an
intermittent positive-pressure breathing device to 24 nonsmoking young adult asth-
matic subjects, fenoterol produced significant improvement in forced expiratory vol-
ume at 1 second (FEy1), in maximum midexpiratory flow (FEFn-75%), and in forced
expiratory flow at 25 per cent of vital capacity (FEF25%) for 6 to 8 hours, whereas
isoproterenol and isoetharine with phenylephrine produced improvement for 1 and 2
hours, respectively. The lowest dosage of fenoterol was as effective as the highest but
had fewer adverse effects.
F ENOTEROL hydrobromide, (1-3,5-dihy-
droxyphenyl)-1-hydroxy-2-(4-hydrox-
yphenylisopropylamino)ethane (TH 1 165a),
structurally related to metaproterenol, is a
relatively selective -adrenergic agonist
with a prolonged duration of action.15 The
purpose of this study was to compare feno-
terol in three different doses with isoprote-
renol, isoetharine combined with phenyl-
ephrine, and a placebo, all delivered with
an intermittent positive-pressure breathing
(IPPB) device to young adults with uncom-
plicated asthma.
Methods
Twenty-four informed volunteer partici-
pants (14 female and 10 male) had asthma
characterized by episodic shortness of breath
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and wheezing brought on by various stim-
uli which changed in severity spontane-
ously and with therapy. They were 18 to 30
years old (average 22 years) and had had
asthma an average of 17 years (range 1 to
30 years). Historically, 23 had reactions to
identified allergens; 21 had hayfever, ec-
zema, and/or hives; and 22 had family
members with atopic disorders. Of the 21
who had been skin tested, all gave histories
of positive immediate reactions. Nineteen
had greater than 5 per cent eosinophils in
their peripheral blood. Twenty-one were
nonsmokers, while three had minimal past
smoking histories (0.14 pack years having
stopped three years ago, 0.12 pack years
having stopped eight years ago, and 3.8
pack years having stopped seven years
ago). None had chronic bronchitis or other
respiratory diseases.
In order to participate, the subjects had to
achieve a 20 per cent improvement in their




























TIME (hrs. after admin.)
Fig. 1. Per cent mean change from baseline of FEy1 following administra-
tion of placebo (--F--); isoproterenol 2.8 mg (--I-); isoetharine 5 mg with
phenylephrine 1.25 mg ( IF ); fenoterol 0.5 mg (--FL--), 1.25 mg (-FM--),
or 2.5 mg (-FH-). * Duration for which change from baseline of the treat-
ment group is significantly greater than the change from baseline of the
placebo group.
within 30 minutes of receiving 0.15mg iso-
proterenol by metered dose inhaler. They
were then excluded if their FEV1 was
greater than 70 per cent of predicted or if
they had cardiac, renal, hepatic, endocrine,
or metabolic disease. Abnormalities of
screening CBC with differential, blood
sugar, BUN, SGOT, total bilirubin, total
protein, albumin, or electrocardiogram also
led to exclusion. Complete physical exam
and history were performed prior to study.
The evaluation was repeated at the comple-
tion of testing.
Studies were done the same time each day
but at least 24 hours apart. No long-acting
bronchodilators were taken for 12 hours,
and no other bronchodilators or cromolyn
sodium were taken for 8 hours prior to or
during testing. A stable dose of beclometh-
asone was continued throughout the study
in three subjects, but otherwise no patient
was receiving corticosteroids.
Spirometry and flow-volume loops were
done in triplicate to obtain the forced expi-
ratory volume at 1 second (FEy1), forced
vital capacity (FVC), maximum midexpira-
tory flow (FEFs-75%), and forced expiratory
flow at 25 per cent of vital capacity (FEFa%).
The measurements from the test giving the
best FEV1 were used. On test days, if the
FEV1 was less than 70 per cent of predicted,
testing was continued and spirometry,
flow-volume loops, blood pressure, and
pulse measurements were done at baseline
and at 5 and 30 minutes and 1, 2, 3,4, 5, 6,
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electrocardiogram was taken at baseline
and at 30 minutes. Testing was discon-
tinued prior to 8 hours if the subject was
symptomatic and the FEV1 had returned to
baseline. During the testing, the patients
were specifically questioned about symp-
toms of nervousness, trembling, palpita-
tion, vertigo, and headache. Patients did
quiet activities during the studies.
Isotonic saline (placebo), fenoterol hydro-
bromide (0.5, 1.25, and 2.5 mg), isoprote-
renol hydrochloride (2.8 mg), or a combina-
tion of isoetharine hydrochloride (5 mg)
with phenylephrine hydrochloride (1.25
mg) in normal saline was administered in
random order (table of random numbers)
with the Porta-Bird (Bird Corp., Palm
Springs, Calif.) IPPB machine using air at
a setting of 15cm H2O. Niether the subjects
nor the physicians administering the pul-
monary function tests knew the identity of
the drug on a test day.
Pulmonary functions were performed
with a rolling seal spirometer (Model 220), a
Pulmo-Norm Digitizer (Model 560), and an
X-Y recorder (Model 750) produced by
Cardio-Pulmonary Instruments Corp., Hous-
ton, Tex.
Statistical analysis of results was carried
out with comparison between paired varia-
bles made with the t-test (significance level
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Fig. 2. Per cent mean change from baseline of FEFzj-m* following administra-
tion of placebo (--F--); isoproterenol 2.8 mg (“-I-”); isoetharine 5 mg with
phenylephrine 1.25 mg ( IP#{149}); fenoterol 0.5 mg (--FL--), 1.25 mg (-FM-) or
2.5mg (-FH-). * Duration for which change from baseline of the treatment
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Fig. 3. Per cent mean change from baseline of FEF.25, following administra-
tion of placebo (--P--); isoproterenol 2.8 mg isoetharine 1.25 mg
(#{149}IP); fenoterol 0.5 mg (--FL--), 1.25 mg (-FM-), or 2.5 mg (-FH-).
* Duration for which change from baseline of the treatment group is signifi-











iables made with Duncan’s multiple range
test (significance level 0.05).
The study design was approved by the
Committee to Review Grants for Clinical
Research and Investigation Involving Hu-
man Beings of the University of Michigan
Medical School. Further information from
the Food and Drug Administration relating
to the increased incidence of “tumors” in
rats receiving albuterol was given to the
participants when it became available dur-
ing the study, and those who had not com-
pleted the study were required to give this
additional consent before continuing.
Results
Testing was discontinued in 20 instances
(four with placebo, four with isoetharine
with phenylephrine, three with isoprote-
renol, and two with each dose of fenoterol)
because the subjects were symptomatic and
the FEy1 had returned to baseline.
There was no significant difference in
baseline FEy1, FEF25-75, and FEF25c, among
treatment groups. Percentage mean changes
in FEy1, FEF25-m, and FEF2, are shown
in Figs. ito 3, and Table I. Fenoterol had a
longer duration of action than either iso-
proterenol or isoetharine with phenyleph-
rifle. The mean changes from baselines in
FEy1 and FEF25, of the three fenoterol
treatment groups were not different at 8
hours. The mean changes from baselines in
FEF25-75, of the three fenoterol treatment
groups were not different at 6 hours. But at
8 hours, the mean change in FEF-m;, was
greater for the 2.5-mg fenoterol treatment
group than for the 1.25-mg fenoterol treat-
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ment group, while the 0.5-mg fenoterol
treatment group was not different from
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The pulse rate increased and was greater
than 100 beats/mm following treatment in
four cases with placebo (highest 120 beats/
Ii o 0 - CC CC N CC ci N mm), in two cases with isoetharine with
a
o in in phenylephrine (highest 136 beats/mm), in
- mincoN-cCC
ba
- 01 01 01 six cases with isoproterenol (highest 132
In beats/mm), in four cases with 0.5 mg feno-ci
terol (highest 126 beats/mm), in two cases
o with 1.25 mg fenoterol (highest 120 beats/
- Il mm), and in three cases with 2.5 mg feno-
.0 C- CO in - terol (highest 120 beats/mm). With the cx-
- - a a1
. o co CC o C- 0 ception of sinus tachycardia, the electro-
- CC N 04 01 CC C1 0 C4
.0 a coicoin.e.coco
.- ci ci ci ci ci ci ci ci cardiograms were normal.
Table II summarizes the adverse expe-
rience with each treatment. The blood
sugar, BUN, SGOT, total bilirubin, total
protein, albumin, and urinalysis were
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bronchial asthma and four with asthmatic
bronchitis with or without emphysema,2
and when administered orally to five pa-
tients with asthma and 15 patients with
combinations of asthma, bronchitis, and/
or emphysema with unspecified smoking
histories.4
In the present study, fenoterol, when ad-
ministered with an intermittent positive-
pressure breathing device to nonsmoking
young adult asthmatic subjects, produced
significant improvement in expiratory flows
at each lung volume as measured by FEV,,
FEF25-?s% and FEF25% for 6 to 8 hours as
shown in Figs. 1,2, and 3. When compared
to placebo, the highest fenoterol dose (2.5
mg) had a longer effect on FEV, and FEF-7s
than the lowest fenoterol dose (0.5 mg);
but when both fenoterol doses were com-
pared to each other, there was no difference.
The duration of action of fenoterol was su-
perior to both isoetharine with phenyleph-
rime (2 hours) and isoproterenol (1 hour).
Previous studies have not investigated
the effect offenoterol on expiratory flows at
low lung volumes. Figure 3 shows that feno-
terol produces prolonged improvement in
the forced expiratory flow at 25 per cent of
vital capacity.
The importance of placebo controls is in-
dicated by the improvement noted in the
placebo treatment group in this study and
others.’34 In addition to the placebo effect,
part of the improvement is probably related
to the natural tendency toward improve-
ment during the first wakeful hours5 and
the subsequent relatively quiet test period.
The experimental design of discontinuing
testing in symptomatic subjects whose
FEy1 had returned to baseline exaggerates
placebo group improvement.
Adverse effects of treatment were least
frequent with 0.5 mg fenoterol; intermedi-
ate in frequency with 1.25 mg fenoterol,
isoetharine with phenylephrine, and iso-
proterenol; and most frequent with 2.5 mg
fenoterol (Table II).
Fenoterol has thus been found to be an
effective bronchodilator for treatment of
asthma in young adult nonsmokers when
delivered by IPPB with a duration of action
of 6 to 8 hours. It has been shown to im-
prove air flows at low lung volumes. In-
creasing the dosage of fenoterol from 0.5
mg to 2.5 mg produced more side effects but
did not improve bronchodilator activity.
References
1. Blackhall MI, Dauth M, Mahoney M,
O’Donnell SR. Inhalation of fenoterol
(Berotec) by asthmatic children. Med
JAust. 1976; 2:439-444.
2. Gemei AM, Miller WF, Miller J, Gast,
LR. Bronchodilator effect of a new
oral beta adrenergic stimulant, TH
1165a. Chest. 1976; 70:460-465.
3. Pennock BE, Rogers RM, Ryan BR,
Ayers LN. Aerosol administration of
fenoterol hydrobromide (Th 1 165a) in
subjects with reversible obstructive
airway disease. Chest. 1977; 72:
731-766.
4. Steen SN, Smith R, Kuo J, Ziment I,
Beall G. Comparison of bronchodila-
tor effects of oral therapy with feno-
terol hydrobromide and ephedrine.
Chest. 1977; 72:291-295.
5. Soutar CA, Costello J, Ijaduola 0,
Turner-Warwidk M. Nocturnal and
morning asthma; relationship to plasma
corticosteroids and response to corti-
cal infusion. Thorax. 1975; 30:436-44 0.
Reprint requests to: Dr. John G. Weg, Pulmonary Divi-
sion, Box 055, University Hospital, S11306, Ann Arbor,
Mich. 48109.
